Would a higher dose make a difference?

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 11
Volume 17
Issue 11

Dr. Von Roenn, from the Robert H. Lurie Comprehensive Cancer Center at Northwestern University in Chicago, commented that “this is a well-conceived and well-implemented trial.”

Dr. Von Roenn, from the Robert H. Lurie Comprehensive Cancer Center at Northwestern University in Chicago, commented that “this is a well-conceived and well-implemented trial.”

She noted that it adds to a relatively small number of studies that have assessed pharmacologic therapy for cancer-related fatigue.

She added, however, that, “one question I have related to the modafi nil study is whether or not a higher dose might in fact make a greater difference.” The findings suggest that the drug will probably not be useful for prevention, at least at the dose tested, she said.

Dr. Von Roenn encouraged ASCO attendees not to forget the benefits of exercise, which improves multiple symptoms and even reduces the risk of recurrence of some cancers. “But as we all know, those studies are very difficult to complete, in part because unfortunately it’s easier to give people a medication than to change lifestyle,” she commented.

Finally, she said that the lack of understanding of the etiology of cancerrelated fatigue is a major barrier to its treatment. “Until we understand the pathogenesis [of fatigue], we are unlikely to have an effective therapy.”

 

The main article can be found here:
Modafinil use curtails severe, treatment-related fatigue

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
2 experts in this video
2 experts in this video
Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
2 experts are featured in this series.
Related Content